| 摘要 |
<p>The invention relates to new substituted naphthyridines of formula (1), as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among -O-R3 or -NR3R4, R3 is C<sub>1-6</sub>-alkyl which is substituted by R5 and R6 R5 is selected from hydrogen, branched or linear C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, -C<sub>1-6</sub>-alkylen-O-C<sub>1-3</sub>-alkyl, C<sub>1-3</sub>-haloalkyl, R6 is ring X wherein n is either 0 or 1, and Formula (I) is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH<sub>2</sub>, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, -C<sub>1-3</sub>-alkyl, -C<sub>1-3</sub>-haloalkyl, -O-C<sub>1-3</sub>-alkyl, -C<sub>1-3</sub>-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.</p> |
